Direct cardiac effects of SGLT2 inhibitors

Sodium-glucose-cotransporter 2 inhibitors (SGLT2is) demonstrate large cardiovascular benefit in both diabetic and non-diabetic, acute and chronic heart failure patients. These inhibitors have on-target (SGLT2 inhibition in the kidney) and off-target effects that likely both contribute to the reporte...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Sha, Coronel, Ruben, Hollmann, Markus W., Weber, Nina C., Zuurbier, Coert J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933888/
https://www.ncbi.nlm.nih.gov/pubmed/35303888
http://dx.doi.org/10.1186/s12933-022-01480-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933888/
https://www.ncbi.nlm.nih.gov/pubmed/35303888
http://dx.doi.org/10.1186/s12933-022-01480-1

Ejemplares similares